Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)
Status:
Unknown status
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the effect of rosuvastatin 10-20 mg on carotid atherosclerosis
progression in Chinese patients by evaluating the change in the percentage of volume of lipid
rich necrotic core (LRNC) using high-resolution magnetic resonance imaging (MRI) after
24-months treatment.